OmeCare, formerly Pathway Genomics, is a privately held global precision medical diagnostic and home-care company with mobile applications.
OmeCare provides a comprehensive set of genomic testing services across the healthcare spectrum, including tests for general health and wellness, liquid biopsy, pharmacogenomics, hereditary cancer risk and carrier screening.
OmeCare was incorporated in 2008. The company is headquartered in San Diego, California. Pathway Genomics was acquired by OME Wellness and re-named OmeCare in Jan 2019.
OmeCare offers both at-home genetic testing and Artificial Intelligence to consumers and physicians to support treatment a variety of health conditions.
OmeCare’s menu ranges from pharmacogenomics testing for well-known drugs like Plavix, codeine, lamotrigine, to general health and wellness testing which includes information on a number of health conditions including obesity management, skincare, ans type 1 and type 2 diabetes and hypertension.
OME has forged a partnership with IBM Watson Group, to help “deliver the first-ever cognitive consumer-facing app based on genetics from a user’s personal makeup.
OmeCare is backed by IBM Watson, Western Technology Investment, Founders Fund and IBM Ventures. The company has raised a total of $43M in funding to date.